News | October 15, 2021
Expect normal quarter in Q2FY22: Emkay
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
Standalone use of Sputnik Light also provides much higher efficacy against severe disease and hospitalizations
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
The drug is being developed at lab scale for the first-line of treatment of Covid-19
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
In collaboration with RAND Europe, the Vitality calculator predicts an individual's healthspan and future health risks
Subscribe To Our Newsletter & Stay Updated
